23 Feb TreeFrog Therapeutics
Mark Rothera, CEO
(Private)
TreeFrog Therapeutics is an R&D-stage biotechnology company set to unlock access to cell-based therapies for patients with unmet needs. TreeFrog’s unique approach combines expertise in biophysics, cell biology and biomanufacturing to address key industry challenges – producing and differentiating high quality cell-based therapies at scale, cost-effectively. TreeFrog has developed a proprietary capsule technology platform C-stem™, which enables amplification of cells at an unprecedented scale and controlled differentiation into microtissues for regenerative medicine applications. To date, the platform has been demonstrated across multiple different cell types and tissues. To advance their purpose of ‘Cell Therapy for All’, TreeFrog operates a hybrid business model that includes programs in Parkinson’s and liver disorders aimed for co-development and out-licensing of the C-Stem platform. The company is open to partnerships with leading biotech and industry players in these and other therapeutics areas.